The promise, problems, and developer concerns explained.

WTI crude surged this week as Iran tensions, Hormuz disruptions, falling U.S. inventories and OPEC+ uncertainty fueled a ...

A community retail project has generated £1m in sales to help more than 50 small independent businesses. Up The Garden Bath, a community interest organisation that upcycles discarded bath tubs, set up ...

DALTON — The town has selected a specialized technology and digital services company to build a new municipal website. At its meeting on April 6, the Select Board unanimously approved commissioning ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Making a video game usually means learning to code, working with complex game engines, and spending hours piecing everything together. That is true even for simple casual games. Many aspiring ...

TL;DR: Unity's upgraded AI, launching in beta at GDC, enables developers to create full casual games using natural language prompts without coding. Leveraging advanced models from OpenAI and Meta, ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...